Stay updated with breaking news from Risk Factor Summary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LEXINGTON - Curis, Inc., , a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor for the treatment of hematologic...
References to the company, our, us or we refer to EVe Mobility Acquisition Corp. The following discussion and analysis of the company's financial condition and results of operations should be read in... | April 14, 2023
Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its business update and financial results for the third quarter... | November 10, 2022
This Annual Report includes forward-looking statements that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and... | March 31, 2022